rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MNKD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Traction
      15h agoYahoo FinanceMNKD
      MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations
      22h agoYahoo FinanceMNKD
      MannKind at UBS Global Biopharma Conference 2026: growth bets widen
      Nov 17Investing.comMNKDUBS
      MannKind: The ReadyFlow Launch Must Fund The Company Built Around It (NASDAQ:MNKD)
      Nov 13Seeking AlphaMNKD
      MannKind: The ReadyFlow Launch Must Fund The Company Built Around It

      Analyst rates MannKind a Hold: Q3 revenue rose 24% to $101.87 million, while repeat demand is unproven and dilution may come before positive cash flow.

      Nov 13Seeking AlphaMNKD
      MannKind's ReadyFlow Launch Keeps The Bull Case Alive (NASDAQ:MNKD)

      MannKind's ReadyFlow could widen Furoscix's reach into more outpatient settings. Click here to read why I rate MNKD stock a speculative Buy.

      Nov 12Seeking AlphaMNKD
      MannKind to Participate in Upcoming Investor Conferences
      Nov 10Yahoo FinanceMNKD
      MannKind (MNKD) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 6The Globe and MailMNKD
      MannKind Corporation Q3 2026 Earnings Call Summary
      Nov 6Yahoo FinanceMNKD
      Cantor Fitzgerald raises MannKind stock price target to $10 on Tyvaso momentum
      Nov 6Investing.comMNKD
      MannKind Corp (MNKD) Q3 2026 Earnings Call Highlights: Revenue Jumps 24% as FuroSix ReadyFlow ...
      Nov 6Yahoo FinanceMNKD
      Is MannKind (MNKD) Trading At A Discount Following Its Mixed Third Quarter Results?
      Nov 6Yahoo FinanceMNKD
      MannKind Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceMNKD
      Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics
      Nov 5Yahoo FinanceMNKD
      MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates
      Nov 5Yahoo FinanceMNKD
      MannKind: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceMNKD
      Can MannKind (MNKD) Still Be A Bargain On Cash Flow?
      Nov 1Yahoo FinanceMNKD
      MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
      Oct 29Yahoo FinanceMNKD
      MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
      Oct 20Yahoo FinanceMNKD
      MannKind at Chardan’s 10th Annual Healthcare Conference: pipeline broadens
      Oct 20Investing.comMNKD
      Learn Why The Bull Case For MannKind Stock Could Change Following Outpatient Diuretic Data
      Oct 20Yahoo FinanceMNKD
      Chardan initiates MannKind stock coverage with buy rating on pipeline
      Oct 19Investing.comMNKD
      This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Hadron E

      Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.

      Oct 19BenzingaMNKD
      Chardan Initiates MannKind at Buy With $10 Price Target
      Oct 19Yahoo FinanceMNKD
      Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation?
      Oct 16Yahoo FinanceMNKD
      MannKind to Participate in the Chardan Healthcare Conference
      Oct 14Yahoo FinanceMNKD
      Truist Financial Keeps Their Buy Rating on MannKind (MNKD)

      Detailed price information for Mannkind Corp (MNKD-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailMNKD
      Steven Binder sells $128,477 of MannKind (MNKD) stock
      Sep 29Investing.comMNKD
      MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

      MannKind (NASDAQ:MNKD) CFO Chris Prentiss outlined the company’s commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase

      Sep 17Yahoo FinanceMNKD
      MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses

      On September 9, MannKind Corporation (NASDAQ:MNKD) announced a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, an inhaled, rapid-acting glucagon-like peptide-1 receptor agonist aimed at weight management. The deal hands MannKind an equity stake in Rose Pharma, a board seat, and royalty rights on future sales, without saddling it with the […]

      Sep 16Yahoo FinanceMNKD
      MannKind at H.C. Wainwright conference: new launches lift outlook
      Sep 15Investing.comMNKD
      MannKind director Steven Binder sells $127,855 in company stock
      Sep 15Investing.comMNKD
      Cantor Fitzgerald reiterates Overweight on MannKind stock at $8
      Sep 11Investing.comMNKD
      Cantor Fitzgerald reiterates Overweight rating on MannKind stock
      Sep 11Investing.comMNKD
      Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
      Sep 9BenzingaMNKD
      MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching

      MannKind and Rose Pharma are partnering to develop an inhaled weight-loss treatment using the Technosphere dry-powder inhalation technology.

      Sep 9Yahoo FinanceMNKD
      MannKind partners with Rose Pharma on inhaled GLP-1 therapy
      Sep 9Investing.comMNKD
      MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

      Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, pat

      Sep 9Yahoo FinanceMNKD
      MannKind, Rose Pharma Sign Deal to Develop Weight-Management Drug
      Sep 9Yahoo FinanceMNKD
      MannKind to Present at Upcoming Investor Conferences

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences: Cantor Global Healthcare Conference (New York, NY)Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET Links to the live

      Sep 2Yahoo FinanceMNKD
      MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative

      MannKind (MNKD) continues to draw attention after recent share price moves, with the stock closing at US$3.95. Investors are weighing its current market value of about US$1.31b against its latest financial profile. Over the past year, MannKind’s share price return has been weak compared with its recent 30 day and 90 day share price returns of 2.60% and 4.77%, while the 1 year total shareholder return declined 13.94%. This suggests that recent momentum is still trying to repair longer term...

      Aug 29Yahoo FinanceMNKD

      This is the newest page. Registered accounts read further back.